PREEMPT Act Targets Maternal Health Crisis with Expanded Medicaid Coverage for Preeclampsia Biomarker Testing

The PREEMPT Act aims to overhaul how we detect preeclampsia, a dangerous pregnancy-related condition that currently causes about 15 percent of maternal deaths in the U.S. By amending Title XIX of the Social Security Act, the bill requires the Secretary of Health and Human Services to provide clear guidance to state Medicaid and CHIP programs within 180 days. This guidance will specifically outline best practices for early screening and management, while clarifying exactly which advanced biomarker tests—including those cleared by the FDA or performed by certified high-complexity labs—are eligible for federal reimbursement. For a pregnant woman in a high-risk group, this could mean the difference between a routine lab visit and a life-threatening emergency room admission.

Modern Tech for Maternal Care

One of the biggest shifts in this bill is the focus on biomarker testing. Currently, many providers rely on older methods like blood pressure checks and urine protein levels, which sometimes catch the condition too late. The PREEMPT Act pushes for the evaluation and coverage of advanced tests that can identify risk much earlier in a pregnancy. For a busy mother working a retail job or a freelance coder without a lot of downtime, early detection means fewer emergency interventions and more predictable prenatal care. By requiring the Secretary to evaluate these 'device-regulated' and 'high-complexity' laboratory tests, the bill aims to standardize a higher level of care for the millions of people covered by Medicaid.

Closing the Gap in Care

The bill explicitly addresses the stark reality that Black women are three times more likely to die from pregnancy-related causes than White women. By focusing on Medicaid and CHIP—programs that cover a significant portion of births in the U.S.—the legislation seeks to put advanced diagnostic tools in the hands of doctors serving the most vulnerable populations. Section 3 of the bill also creates a fast-track for states, requiring the federal government to provide technical assistance within 30 days if a state is unsure about how to cover a specific test. This is designed to prevent bureaucratic red tape from delaying the rollout of life-saving screenings in local clinics.

The Bottom Line on Costs

Preeclampsia isn't just a health crisis; it’s an economic one, costing the U.S. over $2 billion annually in medical expenses and lost productivity. The PREEMPT Act looks to mitigate these costs by preventing the complications that lead to 15 to 20 percent of all preterm births. For families, avoiding a weeks-long NICU stay or long-term cardiovascular issues for the mother isn't just a health win—it's a financial necessity. While the bill focuses on Medicaid, the standards it sets for 'best practices' often ripple out into the private insurance market, potentially raising the bar for maternal care across the board.